Psychosis during pregnancy: Treatment considerations

Annals of Clinical Psychiatry

Volumn 9, Issue 3, 1997, Pages 175-179

  Pinkofsky, Harold B ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Antipsychotics; Molindone; Neuroleptics; Pregnancy; Psychosis

Indexed keywords

MOLINDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CASE REPORT; DRUG HALF LIFE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYDROPHILICITY; HYPOTENSION; MEDICAL DECISION MAKING; PERINATAL PERIOD; PREGNANCY; PRIORITY JOURNAL; PSYCHOSIS; RISK; RISK BENEFIT ANALYSIS; SEDATION; TERATOGENICITY; TREATMENT PLANNING; UTERUS BLOOD FLOW;

ADULT; ANTIPSYCHOTIC AGENTS; DECISION MAKING; FEMALE; HUMANS; MOLINDONE; PREGNANCY; PREGNANCY COMPLICATIONS; PSYCHOTIC DISORDERS;

EID: 0030733774     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026234125565     Document Type: Article

References (40)

1. Wisner KL, Peindl K, Hanusa BH: Symptomatology of affective and psychotic illnesses related to childbearing. J Affect Disorder 1994; 30:77-87
2. Nurnberg HG: An overview of somatic treatment of psychosis during pregnancy and postpartum. Gen Hosp Psychiatry 1989; 11:328-338
3. Mortola JF: The use of psychotropic agents in pregnancy and lactation. Psychiatr Clin North Am 1989; 12:69-87
4. Edlund MJ, Craig TJ: Antipsychotic drug use and birth defects: An epidemologic reassessment. Compr Psychiatry 1984; 25:32-37
5. Kopelman AE, McCullar FW, Heggeness L: Limb malformation following maternal use of haloperidol. JAMA 1975; 231:62-64
6. Hanson JW, Oakley GP: Haloperidol and limb deformity. JAMA 1975; 231:26 (letter)
7. Wan Waes A, Van De Velde E: Safety evaluation of haloperidol in the treatment of hyperemesis gravidarum. J Clin Pharmacol 1969; 9:224-227
8. Godet PF, Marie-Cardine M: Neuroleptiques, schizophrene et grosesse. L'Encephale 1991; 17:543-547
9. Anath J: Congenital malformations with psychopharmacologic agents. Compr Psychiatry 1975; 16:437-445
10. Moriarty AJ, Nance MR: Trifluoperazine and pregnancy. Can Med Assoc J 1963; 88:375-376 (letter)
11. Rumeau-Rouquette C, Goujard J, Huel G: Possible teratogenic effects of phenothiazine in human beings. Teratology 1977; 15:57-64
12. Milkovich L, Van Den Berg BJ: An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynenecol 1976; 125:244-248
13. Sobel DE: Fetal damage due to ECT, insulin, coma, chlorpromazine, or reserpine. Arch Gen Psychiatry 1960; 2:606-611
14. Wrede G, Mednick SA, Huttunen MO, Nilsson CG: Pregnancy and delivery complications in the births of an unselected series of Finnish children with schizophrenic mothers. Acta Psychiatr Scand 1980; 62:369-381
15. Auerbach JG, Hans SL, Marcus J, Maeir S: Maternal psychotropic medications and neonatal behavior. Neurotoxicol Teratol 1992; 14:339-406
16. Hill RM, Desmond MM, Kay JL: Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr 1966; 69:589-595
17. Tamer A, McKey R, Arias D, Worley L, Fogel BJ: Phenothiazine-induced extrapyramidal dysfuntion in the neonate. J Pediatr 1969; 75:479-480
18. Falterman CG, Richardson CJ: Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 1980; 97:308-310
19. Scokel P, Jones WN: Infant jaundice after phenothiazines. Obstet Gynecol 1962; 20:124-127
20. Kris E: Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res Clin Exp 1965; 7:785-789
21. Ayd FJ: Children born to mothers treated with chlorpromazine during pregnancy. Clin Med 1964; 71:1758-1763
22. Gelenberg AJ: Psychosis. In: Gelenberg AJ, Bassuk EL, Schoonover SC, eds. The Practitioner's Guide to Psychoactive Drugs, 3rd ed. New York: Plenum Press; 1991:125-178
23. Freedberg KA, Innis RB, Creese I, Snyder SH: Antischizophrenic drugs: differential plasma binding and therapeutic activity. Life Sci 1979; 24:2467-2474
24. Baldessarini RG: Drugs and the treatment of psychiatric disorders. In: Hardman JG, Limbird LE, Molinoff PG, Ruddon RW, Gilman AG, eds. Goodman and Gillman's the Pharmacologic Basis of Therapeutics, 9th ed. New York: McGraw-Hill; 1996:399-430
25. Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation, 4th ed. Baltimore: Williams and Wilkins; 1994
26. Nahas G, Gougard J: Phenothiazines, benzodiazepines and the fetus. In: Scarpelli EM, Cosmi ED, eds. Reviews in Perinatal Medicine. New York: Raven Press; 1979:243-280
27. Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC: Williams Obstetrics, 19th ed. Norwalk, CT: Appleton and Lange; 1993:225-230
28. Oliver AP, Luchins DJ, Wyatt RJ: Neuroleptic induced seizures. An in vitro technique for assessing relative risk. Arch Gen Psychiatry 1982; 39:206-209
29. Gardos G, Cole JO: Weight reduction in schizophrenics by molindone. Am J Psychiatry 1977; 134:302-304
30. Parent MM, Roy S, Sramek J, Lawson W, Herrera J: Effect of molindone on weight change in hospitalized schizophrenic patients. Drug Intell Clin Pharm 1986; 20:873-875
31. Richelson ER: Neuroleptic affinities for human brain receptor and their use in predicting adverse effects. J Clin Psychiatry 1984; 45:331-336
32. Richelson ER: Pharmacology of neuroleptics in use in the United States. J Clin Psychiatry 1985; 46(8 sec 2):8-14
33. Jenkins SC, Hansen MR: A Pocket Reference for Psychiatrists, 2nd ed. Washington, DC: American Psychiatric Press; 1995:148
34. Ayd FJ: Moban: First of a new class of neuroleptics. In: Ayd FJ, ed. Rational Psychophamacotherapy and the Right to Treatment. Baltimore: Ayd Medical Communications; 1975: 91-105
35. Janicak PG, Davis JM, Preskorn SH, Ayd FJ: Principles and Practice of Psychopharmacotherapy. Baltimore: Williams and Wilkins; 1993:481-484
36. Carpenter WT, Hanlon TE, Heinrichs DW, et al: Continuous versus targeted medication in schizophrenic outpatients: outcomes results. Am J Psychiatry 1990; 147:1138-1148
37. Cohen BM, Babb S, Campbell A, Baldessarini RJ: Presistence of haloperidol in the brain. Arch Gen Psychiatry 1988; 45:879-880 (letter)
38. Sakalis G, Curry SH, Mould GP, Lader MH: Psychologic and clinical effects of chlopromazine and their relationship to plasma level. Clin Pharmacol Ther 1972; 13:931-946
39. Physicians' Desk Reference, 51st ed. Montvale: Medical Economics Data Production Company; 1997:1350, 2379
40. Jann MW: Clozapine. Pharmacotherapy 1991; 11:179-195